Jasmine R Elison1, Jessica E Weinstein2, Kristopher G Sheets3, Cornelius E Regan1, Jennifer J Lentz1,4, Maria Reinoso1, William C Gordon1,4, Nicolas G Bazan1,4. 1. a Department of Ophthalmology, School of Medicine , Louisiana State University Health Sciences Center , New Orleans , LA , USA. 2. b Department of Ophthalmology , University of Washington , Seattle , WA , USA. 3. c Naval Oceanographic Office , Stennis Space Center , MS , USA. 4. d Neuroscience Center of Excellence, School of Medicine , Louisiana State University Health Sciences Center , New Orleans , LA , USA.
Abstract
BACKGROUND: The phospholipid mediator platelet-activating factor (PAF) activates an inflammatory response that includes arachidonic acid release and prostaglandin production in the eye, increasing vascular permeability and inflammation. The purpose of this study is to investigate the action of LAU-0901, a novel PAF receptor antagonist, on experimental uveitis. METHODS: Uveitis was induced in Lewis rats by lipopolysaccharide treatment. LAU-0901 was then delivered systemically in different concentrations at plus 4 and 16 hours, or vehicle injected as controls. Additional animals were used for histological analyses of untreated, uveitis, and uveitis-plus-LAU-0901 retinas. Conventional histological and immunohistochemical methods were employed. A slit lamp and Spectral Domain-Ocular Coherence Tomography (SD-OCT) retinal imager was used for anterior segment photography and posterior pole OCT. Rats were euthanized 4 hours after the second LAU-0901 injection in this 24-hour model. Aqueous humor was collected and quantified, and also analyzed for tumor necrosis factor alpha (TNF-α). RESULTS: Uveitic eyes demonstrated hypopyon formation, leukocyte infiltration, and an increase in aqueous protein and TNF-α levels. LAU-0901 treatment resulted in a dose-dependent reduction in inflammation, reflected by reduced total protein levels (up to a 64% reduction). Moreover, hypopyon was prevented, leukocytes were absent in vitreous and aqueous humor, and TNF-α levels were reduced by 91%. CONCLUSIONS: The PAF receptor antagonist LAU-0901 decreases ocular inflammation in a rat model of anterior uveitis in a dose-dependent manner, suggesting that use of this molecule may provide a means to attenuate inflammation onset and offer a future alternative or adjunctive treatment for ocular inflammation.
BACKGROUND: The phospholipid mediator platelet-activating factor (PAF) activates an inflammatory response that includes arachidonic acid release and prostaglandin production in the eye, increasing vascular permeability and inflammation. The purpose of this study is to investigate the action of LAU-0901, a novel PAF receptor antagonist, on experimental uveitis. METHODS:Uveitis was induced in Lewis rats by lipopolysaccharide treatment. LAU-0901 was then delivered systemically in different concentrations at plus 4 and 16 hours, or vehicle injected as controls. Additional animals were used for histological analyses of untreated, uveitis, and uveitis-plus-LAU-0901 retinas. Conventional histological and immunohistochemical methods were employed. A slit lamp and Spectral Domain-Ocular Coherence Tomography (SD-OCT) retinal imager was used for anterior segment photography and posterior pole OCT. Rats were euthanized 4 hours after the second LAU-0901 injection in this 24-hour model. Aqueous humor was collected and quantified, and also analyzed for tumor necrosis factor alpha (TNF-α). RESULTS:Uveitic eyes demonstrated hypopyon formation, leukocyte infiltration, and an increase in aqueous protein and TNF-α levels. LAU-0901 treatment resulted in a dose-dependent reduction in inflammation, reflected by reduced total protein levels (up to a 64% reduction). Moreover, hypopyon was prevented, leukocytes were absent in vitreous and aqueous humor, and TNF-α levels were reduced by 91%. CONCLUSIONS: The PAF receptor antagonist LAU-0901decreases ocular inflammation in a rat model of anterior uveitis in a dose-dependent manner, suggesting that use of this molecule may provide a means to attenuate inflammation onset and offer a future alternative or adjunctive treatment for ocular inflammation.
Authors: Ludmila Belayev; Larissa Khoutorova; Kristal Atkins; William C Gordon; Julio Alvarez-Builla; Nicolas G Bazan Journal: Exp Neurol Date: 2008-08-28 Impact factor: 5.330
Authors: Y De Kozak; J P Faure; B Thillaye; M M Ruchoux; M Doly; M T Droy-Lefaix; P Braquet Journal: Ocul Immunol Inflamm Date: 1994 Impact factor: 3.070
Authors: Glenn J Jaffe; Andrew D Dick; Antoine P Brézin; Quan Dong Nguyen; Jennifer E Thorne; Philippe Kestelyn; Talin Barisani-Asenbauer; Pablo Franco; Arnd Heiligenhaus; David Scales; David S Chu; Anne Camez; Nisha V Kwatra; Alexandra P Song; Martina Kron; Samir Tari; Eric B Suhler Journal: N Engl J Med Date: 2016-09-08 Impact factor: 91.245
Authors: Dmitry V Chistyakov; Viktoriia E Baksheeva; Veronika V Tiulina; Sergei V Goriainov; Nadezhda V Azbukina; Olga S Gancharova; Eugene A Arifulin; Sergey V Komarov; Viktor V Chistyakov; Natalia K Tikhomirova; Andrey A Zamyatnin; Pavel P Philippov; Ivan I Senin; Marina G Sergeeva; Evgeni Yu Zernii Journal: Int J Mol Sci Date: 2020-01-21 Impact factor: 5.923